Summary
Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore, improve the tolerance to the treatment. Using the model of isolated perfused rat heart, we have evaluated the cardiotoxicity of a novel prodrug of doxorubicin, HMR-1826, which consists of the association of doxorubicin to glucuronic acid. We have compared the cardiac effects (developed pressure, contractility and relaxation of the left ventricle) induced by HMR-1826 to those induced by doxorubicin and Doxil, a liposomal form of doxorubicin. HMR-1826 was administered intravenously every other day for 11 days at doses of 50–200 mg kg–1 per injection while doxorubicin was administered according to the same protocol at doses of 1–3 mg kg–1 per injection. Doxorubicin strongly decreased the cardiac functional parameters at the doses of 2.5 and 3 mg kg–1 per injection. Doxil (3 mg kg–1) and HMR-1826 (50–150 mg kg–1) were largely devoid of cardiotoxicity. HMR-1826 only induced significant alterations of the cardiac function at the highest dose used (200 mg kg–1 per injection). These alterations were much lower than those of doxorubicin at 2.5 mg kg–1 per injection, despite similar general toxicity symptoms (weight loss, nose bleeding and diarrhoea) at these respective doses. Thus, HMR-1826 appeared about 100-fold less cardiotoxic than doxorubicin.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baurain, R, Deprez-De Campaneere, D & Trouet, A (1979). Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal Biochem 94: 112–116.
Bosslet, K, Straub, R, Blumrich, M, Czech, J, Gerken, M, Sperker, B, Kroemer, HK, Gesson, JP, Koch, M & Monneret, C (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58: 1195–1201.
Connors, TA & Whisson, ME (1966). Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210: 866–867.
Duncan, R, Coatsworth, JK & Burtles, S (1998). Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Human Exp Toxicol 17: 93–104.
Florent, JC, Gaudel, G, Mitaku, S, Monneret, C, Gesson, JP, Jacquesy, JC, Mondon, J, Martine, C, Renoux, B, Adrianomenjanahary, S, Michel, S, Koch, M, Tillequin, F, Gerken, M, Czech, J, Straub, R & Bosslet, K (1998). Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem 41: 3572–3581.
Lorell, BH, Wexler, LF, Momomura, S, Weinberg, E & Apstein, CS (1986). The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ Res 58: 653–663.
Mouridsen, HT (1992). Systemic therapy for advanced breast cancer. Drugs 44: 17–28.
Muerdter, TE, Sperker, B, Kivistö, KT, McClellan, M, Fritz, P, Friedel, G, Linder, A, Bosslet, K, Toomes, H, Dierkesmann, R & Kroemer, HK (1997). Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug. Cancer Res 57: 2440–2445.
Pouna, P, Bonoron-Adèle, S, Gouverneur, G, Tariosse, L, Besse, P & Robert, J (1996). Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 117: 1593–1599.
Von Hoff, DD, Layard, MW, Basa, P, Davis, HL, Von Hoff, AL, Rozencweig, M & Muggia, FM (1979). Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710–717.
Working, PK & Dayan, AD (1996). Pharmacological-toxicological expert report: Caelyx™ (Stealth® liposomal doxorubicin HCl). Human Exp Toxicol 15: 752–785.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Platel, D., Bonoron-Adèle, S., Dix, R. et al. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Br J Cancer 81, 24–27 (1999). https://doi.org/10.1038/sj.bjc.6690646
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690646
Keywords
This article is cited by
-
Long-term and short-term models for studying anthracycline cardiotoxicity and protectors
Cardiovascular Toxicology (2007)
-
Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy
Gene Therapy (2001)